Arcellx Announces Pricing of Initial Public Offering

Published on : Published by : BioBuzz Media

GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) – Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expe

Context Therapeutics Doses First Patient in Breast Cancer Trial

Published on : Published by : Alex Keown

Coming off a $28.75 million initial public offering last week, Context Therapeutics dosed its first patient in a mid-stage breast cancer study assessing the combination of the progesterone receptor ONA-XR in combination with an estrogen receptor antagonist.

Philadelphia biopharm firm Context Therapeutics files plans for IPO

Published on : Published by : Chris Frew

Another local life sciences company is looking to go public.
Context Therapeutics, a Philadelphia biopharmaceutical company focused on women’s cancers, is seeking to raise about $20 million through its IPO.
In documents filed Monday with the Securities and Exchange Commission, Context states it intends to sell 1.5 shares million of its common stock to the public at $12 to $14 per share.
The company is poised to become the fifth Philadelphia-area life sciences to complete an IPO this year. That distinction, however, could go to Castle Creek Biosciences, a cell and gene therapy company based in Exton that filed plans to go public through a $100 million IPO in July. Neither company has set a specific date for their public offering.
Context plans to list its stock on Nasdaq under the symbol “CNTX.”

Gain Raises $40 Million in IPO, Funds Will Advance Rare Disease Pipeline

Published on : Published by : Alex Keown

Gain Therapeutics made its debut on the Nasdaq Thursday with a $40 million initial public offering. The company will use the funds to advance the development of its pipeline of therapeutics for rare genetic diseases characterized by protein misfolding.

5 Questions with Brian Hahn, Senior Vice President & CFO, GlycoMimetics

Published on : Published by : Andy Eckert

Mr. Hahn has more than 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as executive director of finance at Middlebrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly-traded specialty pharmaceutical company.

Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO

William Hearl - CEO, Chairman of the Board, and Founder of Immunic Therapeutics
Published on : Published by : Steven Surdez

Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising [….]

BioHealth Capital Region Startups Raised More Than $739M in 2019

Published on : Published by : Chris Frew

BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]